BioVie Inc.
BIVIAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Oppenheimer | maintain | Outperform | Nov 30, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Aug 22, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Jul 18, 2023 |
| Oppenheimer | maintain | Outperform | May 17, 2023 |
| Cantor Fitzgerald | maintain | Overweight | May 17, 2023 |
| Oppenheimer | maintain | Outperform | Feb 14, 2023 |
| EF Hutton | maintain | Buy | Sep 28, 2022 |
| Cantor Fitzgerald | maintain | Overweight | Jul 22, 2022 |
| EF Hutton | maintain | Buy | Mar 17, 2022 |
| Oppenheimer | maintain | Outperform | Mar 15, 2022 |
| B. Riley Securities | maintain | Buy | Nov 30, 2021 |
| B. Riley FBR | maintain | Buy | Jan 15, 2021 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-0.68 | — | — | — |
| Aug 12, 2026 | $-0.70 | $-0.52 | — | — |
| May 11, 2026 | $-0.70 | $-0.73 | — | — |
| Feb 10, 2026 | $-0.77 | $-0.81 | — | — |
| Nov 10, 2025 | $-0.98 | $-0.79 | — | — |
| Aug 15, 2025 | $-1.82 | $-1.82 | — | — |
| May 12, 2025 | $-1.50 | $-3.20 | — | — |
| Feb 11, 2025 | $-4.60 | $-16.00 | — | — |
News
CARSON CITY, Nev., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 2,962,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.60 per share in a…
CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present a late-breaking oral presentation at the 4th Long COVID International Conference 2026 to be held in Nice, France from November 12-13, 2026.
BioVie Inc. (NASDAQ: BIVI - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 544,444 shares, a decline of 34.5% from the September 30th total of 831,296 shares. Currently, 7.5% of the shares of the company are short
CARSON CITY, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop, hosted by the National Institute of Allergy and Infectious Diseases (NIAID) and the Foundation for the National Institutes of Health (FNIH) from November…
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson's drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological Association's annual meeting in San Diego. The randomized, double-blind, placebo-controlled trial enrolled 57 patients, who received bezisterim or placebo for 12 weeks.
Parkinson's patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its Phase 2 ADDRESS-LC trial found that bezisterim delivered the greatest benefits in Long COVID patients with more severe baseline fatigue, post-exertional malaise (PEM) or cognitive impairment, with statistically significant improvements across multiple measures. The results were presented at the American Neurological Association's annual meeting in San Diego, and the abstract was published in Annals of Neurology.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will present results from two Phase 2 trials of its experimental drug bezisterim, in Long COVID and Parkinson's disease, at the American Neurological Association's annual meeting in San Diego. The company said both abstracts were accepted as poster presentations at ANA2026, which runs from October 17 to 20.
CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company's ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson's Disease have been accepted for presentation at ANA2026, the annual meeting of the American Neurological Associ…
BioVie (NASDAQ: BIVI) outlined Phase II results for its investigational drug bezisterim in Long COVID and Parkinson's disease, while detailing plans to seek FDA feedback on potential Phase III programs. President and CEO Cuong Do said the company's two principal assets are bezisterim, an oral small-molecule treatment candidate intended to modulate inflammation, and BIV201, a candidate
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
Clinical-stage biopharmaceutical firm BioVie Inc. (NASDAQ:BIVI) stock is trading lower after the company shared topline results from its Phase 2 ADDRESS-LC study evaluating bezisterim in Long COVID patients.
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)
4:15pm: Oil spike hits stocks US stocks closed sharply lower on Tuesday as surging oil prices revived inflation worries and pushed investors to reassess the...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson's disease clinical development experts to finalize the design of a Phase 3 trial.
Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease
3:40pm: Small cap wrap BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the final on-treatment visit in its Phase 2 ADDRESS-LC trial evaluating...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.